Posts Tagged ‘Dry Eye’
LacriPen Writing Exciting Script for Founders
Interview
Read MoreWelcome & Chairman’s 2015 Year in Review
Presenter: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals. View Full Profile
Read MoreLacriScience
LacriScience is in late stage development of its LacriPen, a portable instrument using gold plated single-use sensors that measures osmolarity to +/- 2 mOSM/L and proteins. By coating the gold film with a specific antibody, such as Adenovirus, Herpes Zoster, Herpes Simplex, or any biomaker, it can be precisely identified or quantified instantly. www.lacripen.com Participant:…
Read MoreForSight VISION5
The company is addressing non-adherence to eyedrops in glaucoma and in ocular hypertension. There remains a true, unmet need to provide clinically relevant intraocular pressure (IOP) reduction with a simple non-invasive product for patients who do not or cannot take their medications. ForSIGHT has developed Helios, a soft, preservative-free ring infused with bimataprost that is…
Read MoreRPS Diagnostics
RPS is a diagnostic company concentrating on inflammatory and infectious disease diagnoses; its flagship product, the InflammaDry, has been designed for in-office diagnosis of inflammatory conditions present in a patient’s eye. The company has devised two platforms: one, an amino-based platform using antibodies to detect disorders. The second, novel platform is a molecular test that…
Read MoreSaunders Speaks to Allergan’s Innovative Culture
Prior to the announcement of the Pfizer-Allergan combination, Allergan CEO and President Brent Saunders spoke with OISTV about how the pharma industry finds and foster innovation, particularly in ophthalmology. Under Saunders, Allergan works hard to “support” rather than “assimilate” new technologies like Oculeve’s neurostimulation-based treatment for Dry Eye. As President and COO of the new…
Read MoreBrent Saunders, President & CEO of Allergan
Brent Saunders delivers a data-packed presentation about the state of innovation in the life sciences industry and discusses where ophthalmology fits into Allergan’s future. Participant: Brent Saunders Brent Saunders has served as CEO and President of Allergan, formerly Actavis, since July 1, 2014. Previously, Mr. Saunders served as CEO and President of Forest Laboratories from…
Read MoreCelniker Gets Eleven Bio Ready For OIS and Conference Season
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 065″] Eleven Biotherapeutics last spring issued some disappointing news when its leading project, EBI-005, didn’t fare well in a Phase III trial for Dry Eye. However, the company’s AMP-Rx platform is chugging along and its EBI-005 is making progress against other conditions including allergic conjunctivitis. CEO and President Abbie C. Celniker,…
Read MoreOra’s Ousler Delves Deep Into Dry Eye
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 064″] Dry Eye remains one of the more dynamic sectors of ophthalmology with Shire’s recent news about its lead Lifitegrast product moving toward FDA approval. Ora knows Dry Eye better than most, and Vice President George Ousler helps fill in the blanks about Dry Eye’s future. Ora also published a paper…
Read MoreQ&A with Shire’s Robert Dempsey
Shire this week announced plans to acquire Foresight Biotherapeutics for $300 million. Robert Dempsey, Shire’s vice president and head of the company’s ophthalmic unit, kindly agreed to answer a few questions about Shire’s push into ophthalmology. In 2013, Shire acquired SARCode and suggested an FDA submission for lifitegrast as a treatment for Dry Eye might…
Read MoreA favorite From The OIS Podcast Stack
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 049″] Oculeve’s stunning acquisition by Allergan last week led us back to a conversation we had with Mark S. Blumenkranz, MD, Professor & Chairman of the Department of Ophthalmology, Stanford University. Mark S. Blumenkranz is the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University. He received…
Read MoreAllergan’s Oculeve Acquisition Bolsters Dry Eye, Medtech
The dry eye space has taken a few hits lately with disappointing clinical news on the biopharmaceutical front. But investors and entrepreneurs developing new treatments have to be bolstered by Allergan’s agreeing to purchase early-stage company Oculeve. According to a press release on the deal, Allergan would pay $125 million up front for Oculeve, which…
Read More